These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25492617)

  • 1. Response to comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by G. Yin, R. Lin and N. Wages.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):23-6. PubMed ID: 25492617
    [No Abstract]   [Full Text] [Related]  

  • 2. Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar.
    Wages NA
    Stat Med; 2015 Jan; 34(1):18-22. PubMed ID: 25492616
    [No Abstract]   [Full Text] [Related]  

  • 3. Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, and S. Zohar.
    Yin G; Lin R
    Stat Med; 2015 Jan; 34(1):13-7. PubMed ID: 25492615
    [No Abstract]   [Full Text] [Related]  

  • 4. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose selection in phase I studies: why we should always go for the most effective.
    Haines IE
    J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose selection in phase I studies: why we should always go for the top.
    Sleijfer S; Wiemer E
    J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
    [No Abstract]   [Full Text] [Related]  

  • 7. Comments on 'A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials' by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2014 May; 33(12):2156-8. PubMed ID: 24797319
    [No Abstract]   [Full Text] [Related]  

  • 8. Building firm foundations for therapy development.
    Dignam JJ; Karrison TG
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25710961
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?
    Wong HH; Halford S
    Lancet Oncol; 2015 Oct; 16(13):1287-8. PubMed ID: 26433816
    [No Abstract]   [Full Text] [Related]  

  • 11. Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies'.
    Riviere MK; Zohar S
    Stat Med; 2016 Feb; 35(3):475-8. PubMed ID: 26757957
    [No Abstract]   [Full Text] [Related]  

  • 12. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designs for phase I trials in ordered groups.
    Conaway MR; Wages NA
    Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adaptive model switching approach for phase I dose-finding trials.
    Daimon T; Zohar S
    Pharm Stat; 2013; 12(4):225-32. PubMed ID: 23801550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-dimensional dose finding in discrete dose space.
    Wang K; Ivanova A
    Biometrics; 2005 Mar; 61(1):217-22. PubMed ID: 15737096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying a maximum tolerated contour in two-dimensional dose finding.
    Wages NA
    Stat Med; 2017 Jan; 36(2):242-253. PubMed ID: 26910586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competing designs for phase I clinical trials: a review.
    Rosenberger WF; Haines LM
    Stat Med; 2002 Sep; 21(18):2757-70. PubMed ID: 12228889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.